|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARHGAP26 |
Gene summary for ARHGAP26 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARHGAP26 | Gene ID | 23092 |
| Gene name | Rho GTPase activating protein 26 | |
| Gene Alias | GRAF | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A0S2Z536 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23092 | ARHGAP26 | CCI_2 | Human | Cervix | CC | 5.52e-14 | 1.83e+00 | 0.5249 |
| 23092 | ARHGAP26 | CCI_3 | Human | Cervix | CC | 7.85e-15 | 1.00e+00 | 0.516 |
| 23092 | ARHGAP26 | Tumor | Human | Cervix | CC | 1.02e-04 | -2.05e-01 | 0.1241 |
| 23092 | ARHGAP26 | T3 | Human | Cervix | CC | 5.75e-04 | -1.86e-01 | 0.1389 |
| 23092 | ARHGAP26 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.77e-15 | -5.66e-01 | 0.0155 |
| 23092 | ARHGAP26 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.75e-03 | -7.07e-01 | 0.0216 |
| 23092 | ARHGAP26 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.47e-11 | 7.10e-01 | -0.0811 |
| 23092 | ARHGAP26 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.72e-08 | 6.94e-01 | -0.1088 |
| 23092 | ARHGAP26 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.18e-10 | 6.49e-01 | -0.1954 |
| 23092 | ARHGAP26 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.11e-03 | 5.23e-01 | -0.059 |
| 23092 | ARHGAP26 | HTA11_2992_2000001011 | Human | Colorectum | SER | 5.97e-03 | -7.91e-02 | -0.1706 |
| 23092 | ARHGAP26 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.31e-27 | -7.80e-01 | 0.096 |
| 23092 | ARHGAP26 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.04e-14 | -5.66e-01 | 0.0674 |
| 23092 | ARHGAP26 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.58e-31 | -7.60e-01 | 0.294 |
| 23092 | ARHGAP26 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.70e-12 | 8.76e-01 | 0.3487 |
| 23092 | ARHGAP26 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.02e-02 | -2.40e-01 | 0.3859 |
| 23092 | ARHGAP26 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.08e-45 | -9.20e-01 | 0.3005 |
| 23092 | ARHGAP26 | F007 | Human | Colorectum | FAP | 2.52e-02 | -2.61e-01 | 0.1176 |
| 23092 | ARHGAP26 | A001-C-207 | Human | Colorectum | FAP | 3.27e-04 | -7.30e-02 | 0.1278 |
| 23092 | ARHGAP26 | A015-C-203 | Human | Colorectum | FAP | 1.47e-33 | -5.27e-01 | -0.1294 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
| GO:0051056 | Colorectum | AD | regulation of small GTPase mediated signal transduction | 94/3918 | 302/18723 | 1.81e-05 | 3.76e-04 | 94 |
| GO:00510561 | Colorectum | MSS | regulation of small GTPase mediated signal transduction | 82/3467 | 302/18723 | 1.31e-04 | 1.99e-03 | 82 |
| GO:00510562 | Colorectum | FAP | regulation of small GTPase mediated signal transduction | 78/2622 | 302/18723 | 3.25e-08 | 2.85e-06 | 78 |
| GO:00510563 | Colorectum | CRC | regulation of small GTPase mediated signal transduction | 69/2078 | 302/18723 | 3.34e-09 | 9.08e-07 | 69 |
| GO:00510567 | Endometrium | AEH | regulation of small GTPase mediated signal transduction | 59/2100 | 302/18723 | 1.43e-05 | 3.03e-04 | 59 |
| GO:005105612 | Endometrium | EEC | regulation of small GTPase mediated signal transduction | 61/2168 | 302/18723 | 9.42e-06 | 2.08e-04 | 61 |
| GO:00510565 | Lung | IAC | regulation of small GTPase mediated signal transduction | 70/2061 | 302/18723 | 9.44e-10 | 1.87e-07 | 70 |
| GO:005105611 | Lung | AIS | regulation of small GTPase mediated signal transduction | 66/1849 | 302/18723 | 4.26e-10 | 9.53e-08 | 66 |
| GO:005105621 | Lung | MIAC | regulation of small GTPase mediated signal transduction | 35/967 | 302/18723 | 6.81e-06 | 6.35e-04 | 35 |
| GO:00510569 | Oral cavity | EOLP | regulation of small GTPase mediated signal transduction | 51/2218 | 302/18723 | 5.67e-03 | 2.92e-02 | 51 |
| GO:005105614 | Oral cavity | NEOLP | regulation of small GTPase mediated signal transduction | 49/2005 | 302/18723 | 2.04e-03 | 1.36e-02 | 49 |
| GO:00510568 | Prostate | BPH | regulation of small GTPase mediated signal transduction | 78/3107 | 302/18723 | 2.69e-05 | 3.16e-04 | 78 |
| GO:005105613 | Prostate | Tumor | regulation of small GTPase mediated signal transduction | 80/3246 | 302/18723 | 3.96e-05 | 4.57e-04 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARHGAP26 | SNV | Missense_Mutation | rs148543665 | c.664N>T | p.Gly222Trp | p.G222W | Q9UNA1 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| ARHGAP26 | SNV | Missense_Mutation | rs369464916 | c.1772C>T | p.Ser591Phe | p.S591F | Q9UNA1 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| ARHGAP26 | SNV | Missense_Mutation | novel | c.1677C>G | p.Ile559Met | p.I559M | Q9UNA1 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ARHGAP26 | SNV | Missense_Mutation | rs374932134 | c.1693N>A | p.Glu565Lys | p.E565K | Q9UNA1 | protein_coding | tolerated(0.14) | possibly_damaging(0.545) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARHGAP26 | SNV | Missense_Mutation | c.775G>C | p.Glu259Gln | p.E259Q | Q9UNA1 | protein_coding | tolerated(0.05) | probably_damaging(0.968) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ARHGAP26 | SNV | Missense_Mutation | c.149N>C | p.Leu50Pro | p.L50P | Q9UNA1 | protein_coding | deleterious(0.02) | possibly_damaging(0.79) | TCGA-AR-A1AX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| ARHGAP26 | SNV | Missense_Mutation | c.2296G>A | p.Ala766Thr | p.A766T | Q9UNA1 | protein_coding | tolerated(0.05) | probably_damaging(0.994) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGAP26 | SNV | Missense_Mutation | c.1709N>T | p.Thr570Ile | p.T570I | Q9UNA1 | protein_coding | tolerated(0.19) | benign(0.097) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGAP26 | SNV | Missense_Mutation | c.661T>A | p.Phe221Ile | p.F221I | Q9UNA1 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ARHGAP26 | SNV | Missense_Mutation | novel | c.1921N>G | p.Leu641Val | p.L641V | Q9UNA1 | protein_coding | tolerated(0.35) | benign(0.034) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |